Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland
Abstract
Aim of study. The aim of this study was to collect and analyse data on relapsing-remitting multiple sclerosis (RRMS) patients receiving disease-modifying therapies (DMTs) in Poland.
Material and methods. This observational, multicentre study with prospective data collection included RRMS patients receiving DMTs reimbursed by the National Health Fund (NFZ) in Poland, monitored by the Therapeutic Programme Monitoring System (SMPT). Demographic profiles, disability status, and treatment modalities were analysed.
Results. Data from 11,632 RRMS patients was collected (from 15,368 new prescriptions), including 10,649 patients in the first-line and 983 in the second-line therapeutic programme of DMTs. The proportion of females to males was 2.39 in the first-line and 1.91 in the second-line. The mean age at DMTs start was 36.6 years in the first-line and 35.1 in the second-line. The median time from the first symptoms to MS diagnosis was 7.4 months, and from MS diagnosis to treatment it was 18.48 months. A total of 43.4% of MS patients started DMT during the 12 months following diagnosis. There was a positive correlation between the duration from MS diagnosis to the start of DMT and a higher initial EDSS value [correlation 0.296 (p < 0.001)]. About 10% of patients stopped DMTs. In Poland, about one third of all MS patients are treated in both lines, and the choice of first-line treatment depends on the region of the country.
Conclusions. In Poland there is a need to increase MS patient access to DMTs by improving the organisation of drug programmes.
Keywords: multiple sclerosisdisease-modifying therapiesPolanddrug programmes
References
- Atlas of MS 2013: Mapping Multiple Sclerosis Around the World. London: Multiple Sclerosis International Federation. 2013.
- Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014; 83(11): 1022–1024.
- Brola W, Sobolewski P, Flaga S, et al. Prevalence and incidence of multiple sclerosis in central Poland, 2010-2014. BMC Neurol. 2016; 16(1): 134.
- Kapica-Topczewska K, Brola W, Fudala M, et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord. 2018; 21: 51–55.
- Trojano M, Bergamaschi R, Amato MP. et. al. Italian Multiple Sclerosis Register Centers Group. The Italian multiple sclerosis register. Neurol Sci. 2019; 40(1): 155–165.
- Kułakowska A, Bartosik-Psujek H, Hożejowski R, et al. Selected aspects of the epidemiology of multiple sclerosis in Poland - a multicentre pilot study. Neurol Neurochir Pol. 2010; 44(5): 443–452.
- Pierzchala K, Adamczyk-Sowa M, Dobrakowski P, et al. Demographic characteristics of MS patients in Poland's upper Silesia region. Int J Neurosci. 2015; 125(5): 344–351.
- Grytten N, Aarseth JH, Lunde HMB, et al. A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. J Neurol Neurosurg Psychiatry. 2016; 87(1): 100–105.
- Westerlind H, Boström I, Stawiarz L, et al. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult Scler. 2014; 20(12): 1578–1583.
- Kingwell E, Zhu F, Marrie RA, et al. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). J Neurol. 2015; 262(10): 2352–2363.
- Kalincik T. Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review. Neuroepidemiology. 2015; 44(4): 199–214.
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–173.
- Izquierdo G, Damas F, Páramo MD, et al. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. PLoS One. 2017; 12(4): e0176174.
- Agius M, Meng X, Chin P, et al. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom. CNS Neurosci Ther. 2014; 20(5): 446–451.
- Trojano M, Butzkueven H, Kappos L, et al. Tysabri® Observational Program (TOP) Investigators. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Mult Scler Relat Disord. 2018; 24: 11–19.
- Cobo-Calvo Á, Bau L, Matas E, et al. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis. Eur Neurol. 2015; 73(3-4): 220–229.
- Brown JW, Coles A, Horakova D, et al. MSBase Study Group. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019; 321(2): 175–187.
- Wilsdon T, Barron A, Mitchell-Heggs A, et al. Access to medicines for multiple sclerosis: challenges and opportunities. CRA Project No. D19380.
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018; 25(2): 215–237.
- Barometr MS 2015. European Multiple Sclerosis Platform Barometr 2015.
- Berger T, Adamczyk-Sowa M, Csépány T, et al. Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Ther Adv Neurol Disord. 2018; 11: 1756286418759189.
